OBJECTIVES In Hungary, resources for anti-cancer chemotherapies are allocated from central budget, based on DRG accounts. The goal of current research was to investigate annual expenditures of first line chemotherapy protocols of metastatic colon cancer of Hungarian patients, especially the contribution of monoclonal antibodies. METHODS A total of 1496 patients' cost data have been collected. Cost analysis of first line chemotherapy protocols has been conducted from the perspective of payer. Irinotecan, cetuximab, bevacizumab, capecitabine and oxaliplatin containing regimens have been analysed for 12 consecutive months. RESULTS Total expenditure of first line colon cancer chemotherapies was US$18.8 million for 12 consecutive months. Average cost per patient was US$12,539 for the investigated period. The share of patients, who have been treated by monoclonal antibodies containing regimens was 16.8%, while cost of biologicals contributed 35% of total first line chemotherapies. CONCLUSIONS The contribution of monoclonal antibodies was relatively low in terms of treated patients in first line chemotherapy of colon cancer. Furthermore, average duration of all chemotherapies were lower than reported in clinical trials, resulting suboptimal administration and cumulative dose of anti-cancer compounds.